



PTO/SB/30 (04-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request  
for  
Continued Examination (RCE)  
Transmittal

Address to:  
Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

|                        |                      |
|------------------------|----------------------|
| Application Number     | 09/987,456           |
| Filing Date            | November 14, 2001    |
| First Named Inventor   | Maurice ZAUDERER     |
| Art Unit               | 1639                 |
| Examiner Name          | Epperson, J.D.       |
| Attorney Docket Number | 1821.0070004/EJH/T-M |

**This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.**

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_

ii. ☐ Other \_\_\_\_\_

b. ☒ Enclosed

i. ☒ Amendment/Reply

iii. ☐ Information Disclosure Statement (IDS)

ii. ☒ Affidavit(s)/ Declaration(s)

iv. ☐ Other \_\_\_\_\_

2. **Miscellaneous**

a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

b. ☐ Other \_\_\_\_\_

3. **Fees**

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

a. ☒ The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 19-0036. I have enclosed a duplicate copy of this sheet.

i. ☐ RCE fee required under 37 CFR 1.17(e)

01 FC:2801

395.00 OP

ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)

iii. ☐ Other \_\_\_\_\_

b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed

c. ☒ Payment by credit card (Form PTO-2038 enclosed)

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

|                   |                        |                  |               |
|-------------------|------------------------|------------------|---------------|
| Signature         | <i>Tracy L. Muller</i> | Date             | July 21, 2005 |
| Name (Print/Type) | Tracy L. Muller        | Registration No. | 55,472        |

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

|                   |  |
|-------------------|--|
| Signature         |  |
| Name (Print/Type) |  |
| Date              |  |

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ZAUDERER *et al.*

Appl. No.: 09/987,456

Filed: November 14, 2001

For: ***In Vitro* Methods of Producing and  
Identifying Immunoglobulin  
Molecules in Eukaryotic Cells**

Confirmation No.: 6770

Art Unit: 1639

Examiner: Epperson, J.D.

Atty. Docket: 1821.0070004/EJH/T-M

**Reply Under 37 C.F.R. § 1.114**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Filed concurrently herewith is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 in the above-captioned application. In reply to the Office Action dated April 21, 2005 (PTO Prosecution File Wrapper Paper No. 20050417) ("the Office Action"), Applicants submit the following Remarks. It is respectfully believed that entry and consideration of this Reply is proper under 37 C.F.R. § 1.114, as this submission is being filed prior to payment of the issue fee, abandonment of the application, or filing of a Notice of Appeal to the U.S. Court of Appeals of the Federal Circuit. This Reply is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting page 3 of this paper, a complete listing of all of the claims:
  - in ascending order;
  - with status identifiers;
- (C) Starting on page 18 of this paper, the Remarks.

There are no amendments to the claims presented herein. The complete listing of the claims beginning on page 3 of this paper is provided as a courtesy.

Attached hereto as Exhibit A is the Declaration of Dr. Walter Storkus, with accompanying Exhibits A1 to A3.

Attached hereto as Exhibit B is the Declaration of Dr. Maurice Zauderer with accompanying Exhibits B1 to B4.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.